All In Biotech

BLA 103691 · Smith and Nephew

Regranex

Becaplermin · Topical · Human Platelet-derived Growth Factor

Novel

Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 16, 1997

Approved uses

3

Original approval plus efficacy supplements

Registered trials

23

5 Phase 3, 2 recruiting

FAERS reports

1

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 8, 2026.

REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use: The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies ( 14.2 ) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology ( 13.2 ) ]. REGRANEX is not intended to be used in wounds that close by primary intention. REGRANEX is a human platelet-derived growth factor indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. REGRANEX is indicated as an adjunct to, and not a substitute for, good ulcer care practices. ( 1 ) Limitations of Use: The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers. ( 1 ) The effects of REGRANEX on exposed joints, tendons, ligaments, and bone have not been established in humans. ( 1 ) REGRANEX is not intended to be used in wounds that close by primary intention. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • REGRANEX · BECAPLERMIN 100UG/G · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Becaplermin" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • abdominal pain lower1
  • ammonia increased1
  • ascites1
  • blood glucose increased1
  • hepatic cirrhosis1
  • hepatic encephalopathy1
  • increased tendency to bruise1
  • international normalised ratio increased1
  • iron deficiency anaemia1
  • lymphoma1
  • pancytopenia1
  • pleural effusion1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Regranex (Becaplermin)

2024 spending

$1.9M

Beneficiaries

794

1,077 claims

Per beneficiary

$2,359

$92.76 per unit

View as table
YearSpending
2020$9,677,047
2021$2,997,028
2022$7,244,933
2023$8,327,758
2024$1,872,885

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 22 on PubMed

Sponsor: Smith and Nephew

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.